CRIS Current Research Information System

CALZA, LEONARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.358
AS - Asia 11.480
EU - Europa 9.879
SA - Sud America 891
AF - Africa 653
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 5
AN - Antartide 1
Totale 35.279
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.244
CN - Cina 3.296
SG - Singapore 3.075
GB - Regno Unito 2.832
VN - Vietnam 2.702
DE - Germania 1.352
IT - Italia 1.171
UA - Ucraina 1.078
SE - Svezia 979
HK - Hong Kong 804
FR - Francia 774
BR - Brasile 661
IN - India 641
RU - Federazione Russa 616
IE - Irlanda 337
JP - Giappone 290
ZA - Sudafrica 233
KR - Corea 179
EE - Estonia 175
NL - Olanda 165
FI - Finlandia 123
TG - Togo 120
SC - Seychelles 106
AR - Argentina 102
CI - Costa d'Avorio 93
PH - Filippine 67
ID - Indonesia 59
BD - Bangladesh 55
BG - Bulgaria 55
TH - Thailandia 50
MX - Messico 49
JO - Giordania 45
CA - Canada 42
AT - Austria 40
CH - Svizzera 37
EC - Ecuador 34
IQ - Iraq 34
NG - Nigeria 26
PL - Polonia 26
CO - Colombia 25
TW - Taiwan 25
GR - Grecia 24
CL - Cile 23
TR - Turchia 23
UZ - Uzbekistan 21
BE - Belgio 20
ES - Italia 20
LB - Libano 20
PK - Pakistan 20
PY - Paraguay 16
SA - Arabia Saudita 15
VE - Venezuela 15
AU - Australia 11
EG - Egitto 11
KE - Kenya 11
PE - Perù 11
ET - Etiopia 10
IR - Iran 10
MA - Marocco 10
PT - Portogallo 10
LT - Lituania 9
RO - Romania 9
MY - Malesia 8
TN - Tunisia 8
NP - Nepal 7
AE - Emirati Arabi Uniti 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
PA - Panama 5
AO - Angola 4
DO - Repubblica Dominicana 4
EU - Europa 4
IL - Israele 4
BO - Bolivia 3
HU - Ungheria 3
KZ - Kazakistan 3
PS - Palestinian Territory 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
AZ - Azerbaigian 2
BS - Bahamas 2
BY - Bielorussia 2
CR - Costa Rica 2
CV - Capo Verde 2
CY - Cipro 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
NI - Nicaragua 2
RS - Serbia 2
TL - Timor Orientale 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BH - Bahrain 1
BN - Brunei Darussalam 1
Totale 35.252
Salva come PNG Salva come JPEG
Città #
Southend 2.518
Singapore 2.013
Ashburn 1.187
Fairfield 1.168
Jacksonville 771
Hong Kong 766
Chandler 707
Wilmington 615
San Jose 598
Santa Clara 596
Hefei 592
Woodbridge 579
Ho Chi Minh City 571
Princeton 556
Seattle 507
Hanoi 489
Houston 466
Dong Ket 417
Cambridge 395
Dublin 337
Ann Arbor 331
Beijing 331
Lauterbourg 327
Boardman 315
Nanjing 274
Tokyo 258
Bologna 256
Westminster 255
Padova 242
Berlin 201
Los Angeles 184
Seoul 151
Saint Petersburg 130
Mülheim 126
Jinan 125
Lomé 120
Buffalo 118
Shenyang 114
Milan 109
The Dalles 109
Helsinki 98
San Diego 94
Abidjan 93
Medford 91
Mahé 90
Nanchang 87
Hebei 81
Changsha 79
Dallas 76
Redondo Beach 76
New York 71
Tianjin 66
Guangzhou 64
Haiphong 64
Frankfurt am Main 57
Zhengzhou 55
Dearborn 54
Sofia 53
São Paulo 53
Da Nang 52
Florence 52
Verona 52
Council Bluffs 51
Hangzhou 50
Jiaxing 50
Amman 45
Shanghai 45
Norwalk 42
Des Moines 41
Nuremberg 41
Bengaluru 40
Falls Church 40
Olalla 40
Chicago 38
Turin 38
Ningbo 37
Yubileyny 37
Redmond 36
Kunming 34
Lanzhou 31
Hải Dương 27
Rio de Janeiro 27
Haikou 26
Phoenix 25
Abeokuta 24
Biên Hòa 24
London 24
Munich 24
Orem 24
Wuhan 24
Bangkok 23
Bühl 23
Can Tho 22
Quận Bình Thạnh 22
Rome 22
Xi'an 21
Shenzhen 20
Taizhou 20
Brussels 19
Falkenstein 19
Totale 22.678
Salva come PNG Salva come JPEG
Nome #
Restriction Factors expression decreases in HIV-1 patients after cART 269
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 238
Acute onset myopericarditis as unusual presentation of primary HIV infection 236
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 233
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 232
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 216
A 2-year survey of bacteriologic profile and antimicrobial susceptibility levels of Enterococci in a large Italian teaching hospital. 211
A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection. 207
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 205
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients. 199
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 199
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 198
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 191
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 187
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. 185
Abacavir-induced febrile agranulocytosis and anaemia. 185
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 185
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 184
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 183
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 181
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. 181
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 181
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues 180
Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. 180
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 179
Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies 178
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 175
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 171
Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological, and imaging response of lung tuberculosis to specific treatment. Which role for linezolid? 171
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 171
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 171
Insulin resistance and diabetes mellitus in HIV-infected patients receiving antiretroviral therapy 170
Molecular Bases of Osteoporosis in HIV: The Role of the Virus and Antiretroviral Therapy 169
Protease inhibitor monotherapy as maintenance regimen in patients with HIV infection. 169
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 168
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 168
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. 168
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 167
HIV and kidney: A dangerous liaison 167
Pancreotoxicity of propofol sedation during purulent meningitis. 166
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 166
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 166
Gynecomastia, lipodystrophy syndrome, and dyslipidemia occurring or worsening during antiretroviral regimens other than protease inhibitor-based ones. 165
Measles outbreak in the city of Bologna, December 2007 to May 2008 165
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 165
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS 165
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 165
A prospective comparison of hepatotoxicity of the two currently available non-nucleoside reverse transcriptase inhibitors in a homogeneous case-mix of HIV-infected patients treated for the first time with efavirenz or nevirapine, according to their different baseline conditions 164
Bone mass loss in patients with human immunodeficiency virus type 1 infection: association with male sex and protease inhibitor therapy 163
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 163
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir 162
Abacavir-lamivudina versus tenofovir-emtricitabina più atazanavir-ritonavir nella semplificazione dell'HAART per dislipidemia 162
Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy 160
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. 159
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. 159
Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine 159
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 158
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. 157
Severe peripheral neuropathy with areflexic and flaccid quadriplegia complicating Legionnaires’ disease in an adult patient. 157
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 155
Methicillin-resistant staphylococci still susceptible to non-beta-lactam antibiotics. What clinical implications in nosocomially-acquired infections? 155
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. 155
First-line efavirenz versus lopinavir/ritonavir-based highly active antiretroviral therapy for naïve patients. 154
Loss of bone mass in chronically HIV-infected patients. Significant association with male gender and protease inhibitor administration 153
Polyunsaturated ethyl esters on n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. 152
Legionnaires' disease associated with macular rash: two cases 152
An observational study of subcutaneous multiple lipomatosis in patients receiving highly active antiretroviral therapy. Possible correlations with metabolic abnormalities and pathogenetic insights 152
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection. 152
Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. 151
Primary Cytomegalovirus infection in otherwise healthy adults with Fever of Unknown Origin: a 3-year prospective survey 151
Antiretroviral therapy voluntarily taken at half-dosage, but fully effective after 6-10 years: a provocative issue for adherence requirements. Case report 151
A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen 150
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. 150
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy 150
Aderenza alla terapia antiretrovirale "autogestita" dai pazienti alla metà della posologia giornaliera raccomandata. Inattesa efficacia immunologica e virologica a lungo termine 148
Cardiovascular prevention in HIV-positive individuals on antiretroviral therapy.. The paradigm shift has already happened: Is it time to wake up and realise it? 146
Changing epidemiology of hepatitis A in the Bologna metropolitan area, northern Italy: importance of counselling and prophylactic measures for the male homo/bisexual population. 145
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 145
Antiretroviral treatment and gynecomastia: which correlations? 144
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. 144
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice 143
Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration 143
Epidemiological, clinical and therapeutic features of AIDS-related Mycobacterium kansasii infection during the HIV pandemic: an 11-year follow-up study. 143
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 143
Bladder carcinoma and HIV infection during the highly active antiretroviral therapy era: a rare, but intriguing association. Two case reports and literature review 143
Comparison between switching therapy from protease inhibitors to an NNRTI and lipid-lowering therapy with pravastatin or bezafibratef for the management of HAART-related dyslipidemia 142
Safety issues about nevirapine administration in HIV-infected pregnant women 142
An extremely different dysmetabolic profile between the two available nonucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. 141
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy? 141
Diffuse skin spread of HIV-associated visceral leishmaniasis: cumbersome diagnostic and therapeutic issues 140
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 140
Stabilizzazione a lungo termine dell'assetto virologico e immunologico dell'infezione da HIV in un "AIDS Presenter" seguito per oltre vent'anni, nonostante la mancata aderenza alla terapia antiretrovirale 139
Renal toxicity associated with antiretroviral therapy 139
Chron’s disease, rare association with selective IgA immunodeficiency, and development of life-threatening bacterial infections. 139
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up 139
Novel understanding on genetic mechanisms of enteric neuropathies leading to severe gut dysmotility 138
Metabolic alterations in human immunodeficiency virus-infected patients treated with antiretroviral therapy 137
Raltegravir use prospectically assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profile 137
Disorders of glucose metabolism and insulin resistance in HIV-infected patients treated with protease inhibitors: considerations on frequency and clinical management, in a prospective, randomized study 136
First-line efavirenz- versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients 136
Totale 16.610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.099
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.099
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.261 0 0 0 0 0 0 0 0 0 231 177 853
2021/20224.312 402 215 284 406 405 262 77 331 146 349 732 703
2022/20233.746 467 596 209 473 237 225 127 188 621 118 361 124
2023/2024867 72 156 63 98 66 158 51 62 25 64 23 29
2024/20254.519 118 901 407 359 976 204 251 89 38 202 81 893
2025/202610.396 709 1.187 1.261 1.003 1.264 661 979 499 2.077 756 0 0
Totale 35.861